Curis, Inc. Shares Promising Updates on Emavusertib Clinical Trials

Curis, Inc., a biotechnology firm traded on NASDAQ under the ticker CRIS, has recently delivered positive updates regarding its drug emavusertib (CA-4948). This small molecule IRAK4 and FLT3 inhibitor is garnering attention in the landscape of lymphoma treatment due to its promising clinical trial results. On July 22, 2026, the company announced a webcast to discuss updated clinical data from the TakeAim Lymphoma study, focusing particularly on Primary CNS Lymphoma (PCNSL) and Chronic Lymphocytic Leukemia (CLL).

During the webcast, Curis CEO James Dentzer expressed excitement about the data emerging from the PCNSL study, noting the novel treatment's potential. The TakeAim Lymphoma study presented compelling figures—achieving a 100% objective response rate (ORR) in BTK-naïve patients and a 33% ORR in patients who were previously treated with BTK inhibitors. These promising results indicate that emavusertib could effectively reverse disease progression for patients who have yet to find success with existing therapies.

In the realm of CLL, Curis has recently expanded its enrollment efforts, successfully consenting ten patients, of which the first five are expected to receive treatment by the end of July 2026. Dentzer also relayed an optimistic update regarding their year-end projections, boosting expectations for data availability from five patients to a new range of five to ten. This increase reflects the heightened engagement from clinical sites and key opinion leaders in the ongoing TakeAim CLL study.

Overview of Emavusertib and Its Mechanism

Emavusertib operates by targeting critical pathways involved in lymphoma and leukemia. Both PCNSL and CLL are characterized by dysregulation of the NF-kB pathway, influenced by two biological routes: BCR and TLR1. By utilizing emavusertib in conjunction with BTK inhibitors, the intention is to effectively block the dual influences on NF-kB, offering new hope for patients resistant to conventional treatments.

In the case of PCNSL, the typical response rates for BTK inhibitors in naive patients range from 40%-70%, but often only partial responses are observed. For those patients progressing after BTK inhibition, options can become drastically limited. The results of initial studies imply that emavusertib may lead to improved outcomes even when initiated after the failure of a BTK monotherapy.

Conversely, the CLL landscape shows more favorable outcomes with BTK inhibitors; however, combining them with emavusertib has the potential to achieve deeper responses, including complete responses and undetectable minimal residual disease (MRD).

Detailed Insights into TakeAim Studies

The TakeAim Lymphoma study is a multi-part clinical evaluation exploring the efficacy of emavusertib in tandem with ibrutinib for PCNSL patients. While Part A has successfully concluded its dose escalation phase, Parts B and C are continuing with specific focus on patients who have prior exposure to BTK inhibitors and those who are naive to BTK therapies, respectively.

Notably, Curis’ ongoing engagement with both the FDA and EMA has paved the way for potential accelerated approval avenues based on encouraging preliminary findings. This proactive approach illustrates Curis’ commitment to timely bringing novel therapies to market for patients in dire need.

Further, the TakeAim CLL study comprises an open-label Phase 2 trial focusing on the integration of emavusertib with zanubrutinib, another BTK inhibitor. The study is explicitly targeting patients in partial response, emphasizing the need for carefully monitored criteria including residual disease evaluations.

Conclusion

Curis, Inc. stands on the precipice of potentially transformative advances in the treatment of both PCNSL and CLL. Their commitment to developing emavusertib is a notable example of how innovative therapies can reshape oncology. As the company progresses through regulatory channels and gathers clinical data, the landscape of lymphoma treatment may soon witness significant improvements that could better patient outcomes, heralding a new chapter in cancer therapy.